MISSISSAUGA, ON, May 18, 2012 /PRNewswire/ - Covalon Technologies Ltd. (the
"Company" or "Covalon") (TSXV: COV), an advanced medical technologies
company, today announced it will be showcasing its advanced medical
coating capabilities, including its SilverCoatTM Antimicrobial Silicone Foley Catheter as well as its recently FDA
cleared IV Clear antimicrobial silicone adhesive film dressing from
May 19th to May 23rd at the American Urological Association 2012 Annual Meeting ("AUA") in
"We are looking forward to presenting our SilverCoat Antimicrobial
Silicone Foley Catheter, with its lubricious and antimicrobial coating
at the AUA," said Brian Pedlar, Covalon's Chief Executive Officer. "We
have demonstrated that our antimicrobial coating outperforms
market-leading silver coated Foley catheters in killing the bacteria
most commonly associated with urinary tract infections. The AUA
provides Covalon with a great opportunity to showcase our urological
care products to an international audience, including close to three
hundred leading manufacturers, wholesalers and distributors."
Urinary tract infections have been identified by the United States
Center for Disease Control as the most common type of healthcare
associated infection, of which 75% are associated with a urinary
catheter, often referred to as CAUTIs. The Centers for MediCare and
Medicaid Services are no longer reimbursing medical institutions for
the treatment of CAUTIs.
Now in its 107th year, the AUA Annual Meeting is the largest gathering
of urologists in the world, providing unparalleled access to
groundbreaking research, new guidelines and the latest advances in
Covalon will also be showcasing its advanced wound and antimicrobial
silicone adhesive technology. These exciting new products will be
available for license or distribution, following regulatory clearance
to our growing domestic and international distribution channels and to
medical product companies who are looking to license breakthrough new
To learn more about Covalon's products and services, please visit us at
booth 3756 in the Georgia World Congress Center from May 19th to 23rd or contact Brian Pedlar, CEO, Covalon Technologies Ltd. at email@example.com.
Covalon Technologies Ltd. researches, develops and commercializes new
healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the
advanced healthcare needs of medical device companies, healthcare
providers and individual consumers. Covalon's technologies are used to
prevent, detect and manage medical conditions in specialty areas such
as wound care, tissue repair, infection control, disease management,
medical device coatings and biocompatibility. To learn more about
Covalon, visit our website at www.covalon.com Follow us on Twitter @covalon
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will",
"should", "could" or "might" occur or be achieved and other similar
expressions. These forward-looking statements involve risk and
uncertainties, including the difficulty in predicting product
approvals, acceptance of and demands for new products, the impact of
the products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which could
cause results, performance, or achievements to differ materially from
the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to
the Company. Investors should consult the Company's ongoing quarterly
filings for additional information on risks and uncertainties relating
to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements whether as
a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.